Monday, 20 May 2019

Aska, Neopharma arm team up for Rs350 Cr venture

27 April 2018 | News

The objective will be to manufacture products targeting chronic therapies.

Image credit- thestoryengine.co

Image credit- thestoryengine.co

Japan based Aska Pharmaceuticals Co. and Omnicare Drugs India Pvt Ltd, a 100 per cent subsidiary of the UAE's largest pharmaceutical manufacturer Neopharma LLC, have established a joint venture (JV) to set up a manufacturing facility in Visakhapatnam.

The focus of this state-of-the-art facility, which will come up by 2020 at the cost of Rs 350 crore, will be to manufacture oral solid dosage forms, oral liquids and topical preparations. It will have a peak capacity to manufacture 3 billion tablets a year.

The objective will be to manufacture products targeting chronic therapies in cardiovascular diseases, central nervous system and diabetes along with other drugs from key therapeutic classes targeting Japan and world market.

The two companies have entered into this agreement with the purpose of manufacturing and marketing of pharmaceuticals to global market.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

 

Survey Box

Will stem cell therapy market witness highest growth in Asia by 2020?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls